Table 1.
Characteristics of the study group patients according to their decisions about vaccination against COVID-19.
| Total Study Group n (%) or Mean (SD) |
Vaccinated n (%) or Mean (SD) |
Unvaccinated n (%) or Mean (SD) |
p-Value Vaccinated vs. Unvaccinated |
|
|---|---|---|---|---|
| Number of patients | 261 (100%) | 200 (77%) | 61 (23%) | |
| Age, years | 60 (18–92) | 62.5 (18–92) | 52.3 (23–87) | 0.005 * |
| Sex, female | 163 (62%) | 126 (63%) | 37 (61%) | 0.78 |
| Duration of disease, years | 7.3 ± 7.1 | 7.5 ± 7.1 | 6.3 ± 7.1 | 0.15 |
| PAH patients | 164 (63%) | 125 (63%) | 39 (64%) | 0.86 |
| Idiopathic PAH | 85 (52%) | 69 (55%) | 24 (41%) | |
| Heritable PAH | 5 (3%) | 3 (2%) | 2 (5%) | |
| PAH associated with CHD | 36 (22%) | 27 (22%) | 9 (23%) | |
| PAH associated with CTD | 30 (18%) | 22 (18%) | 8 (20%) | |
| PAH porto-pulmonary | 6 (4%) | 3 (2%) | 3 (8%) | |
| Drug-induced PAH | 1 (0.5%) | 1 (1%) | 0 | |
| PAH associated with HIV | 1 (0.5%) | 0 | 1 (3%) | |
| PAH monotherapy | 48 (29%) | 38 (30%) | 10 (26%) | 0.76 |
| PAH two drugs | 59 (36%) | 41 (33%) | 18 (46%) | |
| PAH three drugs | 57 (35%) | 46 (37%) | 11 (28%) | |
| CTEPH patients | 97 (37%) | 75 (37%) | 22 (36%) | 0.86 |
| CTEPH-BPA | 73 (75%) | 57 (76%) | 16 (73%) | 0.82 |
| CTEPH-PEA | 22 (23%) | 16 (21%) | 6 (27%) | 0.68 |
| CTEPH monotherapy (riociguat or sildenafil) |
75 (77%) | 56 (75%) | 19 (86%) | 0.41 |
| WHO functional class | 2.4 ± 0.7 | 2.4 ± 0.7 | 2.4 ± 0.8 | 0.92 |
| 1 | 22 (8%) | 15 (8%) | 7 (11%) | |
| 2 | 119 (46%) | 94 (47%) | 25 (41%) | |
| 3 | 108 (41%) | 83 (41%) | 25 (41%) | |
| 4 | 12 (5%) | 8 (4%) | 4 (7%) | |
| COVID-19 disease | 44 (17%) | 31 (16%) | 13 (21%) | 0.49 |
| Anticoagulation | 126 (48.3%) | 99 (49.5%) | 27 (44.3%) | 0.54 |
| Concomitant disease | 165 (63%) | 130 (65%) | 57 (75%) | 0.36 |
| Arterial hypertension | 117 (45%) | 96 (48%) | 40 (53%) | 0.10 |
| Diabetes | 43 (16%) | 35 (18%) | 12 (16%) | 0.60 |
| COPD | 23 (9%) | 19 (10%) | 9 (12%) | 0.73 |
| Coronary artery disease | 44 (17%) | 37 (19%) | 10 (13%) | 0.41 |
| Neoplasm | 29 (11%) | 18 (9%) | 10 (13%) | 0.29 |
| Obesity, BMI ≥ 30 kg/m2 | 70 (27%) | 54 (27%) | 23 (30%) | 0.92 |
| Fear of COVID-19 | 19 (7–35) | 19 (7–35) | 16 (7–35) | 0.037 ** |
| HADS-A ≥ 8 | 78 (30%) | 61 (31%) | 17 (28%) | 0.70 |
| HADS-D ≥ 8 | 51 (20%) | 36 (18%) | 15 (25%) | 0.48 |
PAH—Pulmonary arterial hypertension, PAH-CHD—Pulmonary arterial hypertension related to congenital heart disease, IPAH—Idiopathic pulmonary arterial hypertension, PAH-CTD—Pulmonary arterial hypertension associated with connective tissue disease, PAH-porto-pulmonary—Pulmonary arterial hypertension associated with portal hypertension, HIV-human immunodeficiency virus, CTEPH—Chronic thromboembolic pulmonary hypertension, BPA—Balloon pulmonary angioplasty, PEA—Pulmonary endarterectomy, COPD—Chronic obstructive pulmonary disease, WHO—World Health Organization, HADS—Hospital Anxiety and Depression Scale, HADS-A—anxiety part, HADS-D—depression part; * Mann-Whitney U test, ** Mann-Whitney U test.